- Home
- ACIU vs JSPR Comparison
ACIU vs JSPR Comparison
Compare ACIU & JSPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACIU
- JSPR
- Stock Information
- Founded
- ACIU 2003
- JSPR 2018
- Country
- ACIU Switzerland
- JSPR United States
- Employees
- ACIU N/A
- JSPR N/A
- Industry
- ACIU Biotechnology: Pharmaceutical Preparations
- JSPR Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ACIU Health Care
- JSPR Health Care
- Exchange
- ACIU Nasdaq
- JSPR Nasdaq
- Market Cap
- ACIU 332.4M
- JSPR 323.0M
- IPO Year
- ACIU 2016
- JSPR N/A
- Fundamental
- Price
- ACIU $3.15
- JSPR $22.48
- Analyst Decision
- ACIU Strong Buy
- JSPR Strong Buy
- Analyst Count
- ACIU 2
- JSPR 11
- Target Price
- ACIU $12.00
- JSPR $73.38
- AVG Volume (30 Days)
- ACIU 153.3K
- JSPR 211.1K
- Earning Date
- ACIU 11-05-2024
- JSPR 11-07-2024
- Dividend Yield
- ACIU N/A
- JSPR N/A
- EPS Growth
- ACIU N/A
- JSPR N/A
- EPS
- ACIU N/A
- JSPR N/A
- Revenue
- ACIU $48,505,404.00
- JSPR N/A
- Revenue This Year
- ACIU $85.33
- JSPR N/A
- Revenue Next Year
- ACIU $80.69
- JSPR N/A
- P/E Ratio
- ACIU N/A
- JSPR N/A
- Revenue Growth
- ACIU 4097200.00
- JSPR N/A
- 52 Week Low
- ACIU $2.25
- JSPR $4.00
- 52 Week High
- ACIU $5.14
- JSPR $31.01
- Technical
- Relative Strength Index (RSI)
- ACIU 45.68
- JSPR 52.21
- Support Level
- ACIU $3.10
- JSPR $20.73
- Resistance Level
- ACIU $3.25
- JSPR $26.05
- Average True Range (ATR)
- ACIU 0.14
- JSPR 1.60
- MACD
- ACIU -0.02
- JSPR -0.10
- Stochastic Oscillator
- ACIU 13.16
- JSPR 48.48
About ACIU AC Immune SA
AC Immune SA is a clinical-stage biopharmaceutical company that focuses on neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The Company has one segment. The Company currently focuses most of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.
About JSPR Jasper Therapeutics Inc.
Jasper Therapeutics Inc is a clinical-stage biotechnology company dedicated to enabling cures through hematopoietic stem cell therapy. It is focused on the development and commercialization of safer and more effective conditioning agents and stem cell engineering to allow for expanded use of stem cell transplantation and ex vivo gene therapy.